TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Study of Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)
Brief Summary: The purpose of this study is to determine if hypertonic saline with and without dextran can improve neurologic outcomes in victims of severe traumatic brain injury (TBI).

Injury and lost blood from trauma can cause your body to go into shock (low blood pressure related to blood loss). This decreased blood flow can lead to organ damage. In order to restore the blood pressure and blood flow, the medics give fluids into the patients' veins as soon as possible. This is called "resuscitation". The fluid most commonly used is "isotonic" or one that is the same salt concentration as the blood. The investigators are trying to determine if infusing a "hypertonic" fluid or one more concentrated than the blood can increase the blood pressure and restore blood flow more efficiently. The hypertonic fluids they are using are called hypertonic saline with dextran (HSD) and hypertonic saline (no dextran). Hypertonic saline is a salt solution that is slightly more concentrated than blood. Dextran is a sugar solution.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline (HS) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% normal saline | Intervention Type: DRUG; Name: 7.5% hypertonic saline/6% Dextran-70 (HSD); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 7.5% hypertonic saline (HS); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 0.9% normal saline; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloids | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Colloids | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Fluid resuscitation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution; Assigned to Arm(s): N/A
D: Arm Label: 7.5% hypertonic saline/6% dextran (HSD); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD) | Arm Label: 7.5% hypertonic saline (HS); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline (HS) | Arm Label: 0.9% normal saline (NS); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline (NS) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD); Assigned to Arm(s): 7.5% hypertonic saline/6% dextran (HSD) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline (HS); Assigned to Arm(s): 7.5% hypertonic saline (HS) | Intervention Type: DRUG; Name: 0.9% Normal Saline (NS); Assigned to Arm(s): 0.9% normal saline (NS)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season
Brief Summary: This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and palivizumab were administered sequentially to high-risk children during the same respiratory syncytial virus (RSV) season. A control group was administered only motavizumab.


Options:
A: Arm Label: MEDI8897; Type: EXPERIMENTAL; Interventions: Drug: MEDI8897 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MEDI8897; Assigned to Arm(s): MEDI8897 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MEDI8897; Type: EXPERIMENTAL; Interventions: Drug: MEDI8897 | Arm Label: Palivizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Palivizumab | Intervention Type: DRUG; Name: MEDI8897; Assigned to Arm(s): MEDI8897 | Intervention Type: DRUG; Name: Palivizumab; Assigned to Arm(s): Palivizumab
C: Arm Label: Palivizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Palivizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Palivizumab; Assigned to Arm(s): Palivizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Motavizumab followed by Palivizumab; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab, palivizumab | Arm Label: Palivizumab followed by motavizumab; Type: EXPERIMENTAL; Interventions: Biological: Palivizumab, motavizumab | Arm Label: Motavizumab control; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab, palivizumab; Assigned to Arm(s): Motavizumab followed by Palivizumab | Intervention Type: BIOLOGICAL; Name: Palivizumab, motavizumab; Assigned to Arm(s): Palivizumab followed by motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab; Assigned to Arm(s): Motavizumab control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season
Brief Summary: This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and palivizumab were administered sequentially to high-risk children during the same respiratory syncytial virus (RSV) season. A control group was administered only motavizumab.


Options:
A: Arm Label: Motavizumab followed by Palivizumab; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab, palivizumab | Arm Label: Palivizumab followed by motavizumab; Type: EXPERIMENTAL; Interventions: Biological: Palivizumab, motavizumab | Arm Label: Motavizumab control; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab, palivizumab; Assigned to Arm(s): Motavizumab followed by Palivizumab | Intervention Type: BIOLOGICAL; Name: Palivizumab, motavizumab; Assigned to Arm(s): Palivizumab followed by motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab; Assigned to Arm(s): Motavizumab control
B: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
C: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
D: Arm Label: Treatment Group A; Type: PLACEBO_COMPARATOR; Interventions: Biological: Formulation buffer | Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: RSV F vaccine with adjuvant | Intervention Type: BIOLOGICAL; Name: RSV F vaccine with adjuvant; Assigned to Arm(s): Treatment Group | Intervention Type: BIOLOGICAL; Name: Formulation buffer; Assigned to Arm(s): Treatment Group A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
Brief Summary: The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. This will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.


Options:
A: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
B: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM
C: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probuphine | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Probuphine; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
Brief Summary: The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. This will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.


Options:
A: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM
B: Arm Label: Active electroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroacupuncture | Arm Label: Sham electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Electroacupuncture | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Active electroacupuncture, Sham electroacupuncture
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
D: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma
Brief Summary: The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.


Options:
A: Arm Label: Lansoprazole; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Lansoprazole; Assigned to Arm(s): Lansoprazole | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Lansoprazole; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Lansoprazole; Assigned to Arm(s): Lansoprazole | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Esomeprazole 40 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Esomeprazole 40 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg twice daily | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo for esomeprazoe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo proton pump inhibitor | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo proton pump inhibitor; Assigned to Arm(s): Placebo for esomeprazoe

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Based Stress Reduction for Hot Flashes
Brief Summary: Stress appears to be related to hot flash frequency and intensity, and the degree of distress that women experience from their hot flashes appears to be related to their coping resources. This trial is a pilot study to test the effect of participation in a mindfulness-based stress reduction program on hot flash frequency and intensity, as well as menopause-related quality of life.


Options:
A: Arm Label: MBSR self care program including weekly sessions; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: MBSR self care program; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MBSR; Assigned to Arm(s): MBSR self care program, MBSR self care program including weekly sessions
B: Arm Label: MBSR 6 Weeks Program; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR 6 Weeks Program | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBSR 6 Weeks Program; Assigned to Arm(s): MBSR 6 Weeks Program
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): 1
D: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk
Brief Summary: In the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used.

Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising strategy to improve prognosis in these patients.

The Risk and Prevention study combines an epidemiological and an experimental approach in order to:

1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study)
2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.


Options:
A: Arm Label: Dietary Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention
B: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk
Brief Summary: In the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used.

Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising strategy to improve prognosis in these patients.

The Risk and Prevention study combines an epidemiological and an experimental approach in order to:

1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study)
2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk
Brief Summary: In the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used.

Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising strategy to improve prognosis in these patients.

The Risk and Prevention study combines an epidemiological and an experimental approach in order to:

1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study)
2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Arm Label: Dietary Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention
D: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin

Answer: A